
The Link Between Oxbryta and Vaso-Occlusive Crises: What Patients Need to Know
Oxbryta, once seen as a promising treatment for Sickle Cell Disease (SCD), aimed to improve hemoglobin levels and reduce the complications of sickle-shaped red blood cells, including acute pain crises. However, its recall in 2024










